title: Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
abstract: Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.
authors.affiliation: Department of Internal Medicine, University of Utah, Salt Lake City, USA.
authors.forename: Sujata
authors.initials: S
authors.lastname: Narayanan
authors.forename: Kristina
authors.initials: K
authors.lastname: Callis-Duffin
authors.forename: Julia
authors.initials: J
authors.lastname: Batten
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib